Inhibikase Therapeutics Inc Financials
This page shows Inhibikase Therapeutics Inc (IKT) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 6 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Equity-funded R&D, not product sales, is the dominant engine shaping Inhibikase's cash runway and balance sheet.
FY2025 ended with cash of$178.8M even though operating cash burn was-$27.8M . Because financing cash flow supplied$108.5M , the bigger cash cushion reflects external funding of the research program rather than a business that is starting to pay for itself.
R&D spending reached
Dilution, not debt, has been the main financing tool: shares outstanding rose to 131.7M from 69.4M over the last year. Even so, balance-sheet pressure remains low because total liabilities were only
Financial Health Signals
Based on FY2025 annual data, averaged across the last 3 years for performance metrics (most-recent year weighted highest). How this score is calculated →
Health score ≠ stock price. This rates the quality of Inhibikase Therapeutics Inc's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Inhibikase Therapeutics Inc carries a low D/E ratio of 0.05, meaning only $0.05 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 100/100, indicating a strong balance sheet with room for future borrowing.
With a current ratio of 21.70, Inhibikase Therapeutics Inc holds $21.70 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 100/100.
Inhibikase Therapeutics Inc generates a -27.9% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 0/100. This is up from -29.0% the prior year.
Inhibikase Therapeutics Inc passes 2 of 9 financial strength tests. 2 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).
For every $1 of reported earnings, Inhibikase Therapeutics Inc generates $0.58 in operating cash flow (-$27.8M OCF vs -$48.3M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Inhibikase Therapeutics Inc earns $-14.0 in operating income for every $1 of interest expense (-$52.0M vs $3.7M). This narrow margin raises concern about the company's ability to service its debt if operating income declines.
Key Financial Metrics
Earnings & Revenue
Inhibikase Therapeutics Inc's EBITDA was -$51.9M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 81.8% from the prior year.
Inhibikase Therapeutics Inc reported -$48.3M in net income in fiscal year 2025. This represents a decrease of 75.4% from the prior year.
Inhibikase Therapeutics Inc earned $-0.49 per diluted share (EPS) in fiscal year 2025. This represents an increase of 57.8% from the prior year.
Cash & Balance Sheet
Inhibikase Therapeutics Inc generated -$27.8M in free cash flow in fiscal year 2025, representing cash available after capex. This represents a decrease of 45.2% from the prior year.
Inhibikase Therapeutics Inc held $178.8M in cash against $0 in long-term debt as of fiscal year 2025.
Inhibikase Therapeutics Inc had 132M shares outstanding in fiscal year 2025. This represents an increase of 89.9% from the prior year.
Margins & Returns
Inhibikase Therapeutics Inc's ROE was -27.9% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 1.1 percentage points from the prior year.
Capital Allocation
Inhibikase Therapeutics Inc invested $29.8M in research and development in fiscal year 2025. This represents an increase of 73.1% from the prior year.
Inhibikase Therapeutics Inc invested $13K in capex in fiscal year 2025, funding long-term assets and infrastructure.
IKT Income Statement
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | N/A | $0 | $0 | $0 | N/A | $0 | $0 |
| Cost of Revenue | $100.0M | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | $10.8M | N/A | $7.6M+45.1% | $5.3M-49.9% | $10.5M | N/A | $4.2M+36.2% | $3.1M |
| SG&A Expenses | $7.4M | N/A | $5.6M-5.2% | $5.9M+12.8% | $5.2M | N/A | $1.6M-17.1% | $2.0M |
| Operating Income | -$17.8M | N/A | -$12.8M-17.9% | -$10.8M+25.8% | -$14.6M | N/A | -$5.8M-15.4% | -$5.1M |
| Interest Expense | $1.5M | N/A | $838K-8.6% | $917K-0.3% | $919K | N/A | $49K-45.7% | $91K |
| Income Tax | $0 | N/A | $0 | $0 | $0 | N/A | $0 | $0 |
| Net Income | -$16.4M | N/A | -$11.9M-20.3% | -$9.9M+27.5% | -$13.7M | N/A | -$5.8M-16.5% | -$5.0M |
| EPS (Diluted) | $-0.10 | N/A | $-0.13-18.2% | $-0.11+26.7% | $-0.15 | N/A | $-0.65 | $-0.66 |
IKT Balance Sheet
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $173.3M-4.3% | $181.2M+127.7% | $79.6M-10.4% | $88.9M-5.8% | $94.3M-4.4% | $98.6M+2152.7% | $4.4M-50.4% | $8.8M |
| Current Assets | $172.2M-4.4% | $180.1M+129.3% | $78.5M-11.6% | $88.8M-5.7% | $94.2M-4.4% | $98.5M+2249.6% | $4.2M-51.3% | $8.6M |
| Cash & Equivalents | $49.6M-72.3% | $178.8M+367.2% | $38.3M-50.8% | $77.7M+5.9% | $73.4M-24.7% | $97.5M+10574.2% | $913K-70.4% | $3.1M |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $5.7M-31.2% | $8.3M+24.0% | $6.7M-23.9% | $8.8M+2.9% | $8.6M+129.0% | $3.7M-23.9% | $4.9M+31.6% | $3.7M |
| Current Liabilities | $5.7M-31.2% | $8.3M+24.0% | $6.7M-23.9% | $8.8M+2.9% | $8.6M+129.0% | $3.7M-23.9% | $4.9M+32.5% | $3.7M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $167.6M-3.1% | $172.9M+137.2% | $72.9M-8.9% | $80.1M-6.6% | $85.7M-9.6% | $94.9M+17979.4% | -$531K-110.4% | $5.1M |
| Retained Earnings | -$159.1M-11.5% | -$142.7M-9.8% | -$129.9M-10.1% | -$118.0M-9.2% | -$108.1M-14.5% | -$94.4M-14.7% | -$82.3M-7.6% | -$76.5M |
IKT Cash Flow Statement
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$12.1M-60.5% | -$7.5M+29.0% | -$10.6M-90.0% | -$5.6M-35.8% | -$4.1M+23.2% | -$5.3M-9.5% | -$4.9M+3.4% | -$5.1M |
| Capital Expenditures | $0 | $0 | $0 | $0-100.0% | $13K | $0 | $0 | $0 |
| Free Cash Flow | -$12.1M-60.5% | -$7.5M+29.0% | -$10.6M-90.0% | -$5.6M-35.4% | -$4.1M+23.0% | -$5.3M-9.5% | -$4.9M+3.4% | -$5.1M |
| Investing Cash Flow | -$80.5M-81323.4% | -$99K+99.7% | -$28.7M-392.0% | $9.8M-53.2% | $21.1M+154.3% | -$38.8M-1634.4% | $2.5M-0.7% | $2.5M |
| Financing Cash Flow | $2.9M-97.3% | $108.6M+81040.4% | -$134K-522.2% | $32K | $0-100.0% | $99.7M+54685.5% | $182K-94.4% | $3.2M |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
IKT Financial Ratios
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Equity | -9.8% | N/A | -16.4%-4.0pp | -12.4%+3.6pp | -16.0% | N/A | N/A | -97.3% |
| Return on Assets | -9.4% | N/A | -15.0%-3.8pp | -11.2%+3.4pp | -14.5% | N/A | -132.0%-75.8pp | -56.2% |
| Current Ratio | 30.14+8.4 | 21.70+10.0 | 11.73+1.6 | 10.09-0.9 | 11.01-15.4 | 26.37+25.5 | 0.85-1.5 | 2.32 |
| Debt-to-Equity | 0.03-0.0 | 0.05-0.0 | 0.09-0.0 | 0.11+0.0 | 0.10+0.1 | 0.04+9.3 | -9.25-10.0 | 0.73 |
| FCF Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Similar Companies
Frequently Asked Questions
Is Inhibikase Therapeutics Inc profitable?
No, Inhibikase Therapeutics Inc (IKT) reported a net income of -$48.3M in fiscal year 2025.
What is Inhibikase Therapeutics Inc's EBITDA?
Inhibikase Therapeutics Inc (IKT) had EBITDA of -$51.9M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Inhibikase Therapeutics Inc's return on equity (ROE)?
Inhibikase Therapeutics Inc (IKT) has a return on equity of -27.9% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Inhibikase Therapeutics Inc's free cash flow?
Inhibikase Therapeutics Inc (IKT) generated -$27.8M in free cash flow during fiscal year 2025. This represents a -45.2% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Inhibikase Therapeutics Inc's operating cash flow?
Inhibikase Therapeutics Inc (IKT) generated -$27.8M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Inhibikase Therapeutics Inc's total assets?
Inhibikase Therapeutics Inc (IKT) had $181.2M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Inhibikase Therapeutics Inc's capital expenditures?
Inhibikase Therapeutics Inc (IKT) invested $13K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Inhibikase Therapeutics Inc spend on research and development?
Inhibikase Therapeutics Inc (IKT) invested $29.8M in research and development during fiscal year 2025.
What is Inhibikase Therapeutics Inc's current ratio?
Inhibikase Therapeutics Inc (IKT) had a current ratio of 21.70 as of fiscal year 2025, which is generally considered healthy.
What is Inhibikase Therapeutics Inc's debt-to-equity ratio?
Inhibikase Therapeutics Inc (IKT) had a debt-to-equity ratio of 0.05 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Inhibikase Therapeutics Inc's return on assets (ROA)?
Inhibikase Therapeutics Inc (IKT) had a return on assets of -26.6% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Inhibikase Therapeutics Inc's cash runway?
Based on fiscal year 2025 data, Inhibikase Therapeutics Inc (IKT) had $178.8M in cash against an annual operating cash burn of $27.8M. This gives an estimated cash runway of approximately 77 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Inhibikase Therapeutics Inc's Piotroski F-Score?
Inhibikase Therapeutics Inc (IKT) has a Piotroski F-Score of 2 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Inhibikase Therapeutics Inc's earnings high quality?
Inhibikase Therapeutics Inc (IKT) has an earnings quality ratio of 0.58x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Inhibikase Therapeutics Inc cover its interest payments?
Inhibikase Therapeutics Inc (IKT) has an interest coverage ratio of -14.0x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Inhibikase Therapeutics Inc?
Inhibikase Therapeutics Inc (IKT) scores 33 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.